Bruno Julianne 4

What Happened

• Bruno Julianne, a director of Damora Therapeutics (DMRA), received a grant of derivative rights covering 37,313 shares on March 23, 2026. The filing reports an acquisition at $0.00 (total reported value $0).
• This was an award of a right to purchase common stock (a derivative grant), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-03-23; Form 4 filed: 2026-03-25 (timely filing).
• Amount granted: 37,313 share‑equivalents; reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided details.
• Footnote: the grant "represents a right to purchase shares" and vests in equal monthly installments through March 23, 2029, subject to continued service.
• Transaction code: A (award/grant of derivative security).

Context

• This is a derivative award that vests over time — the recipient does not receive all shares immediately and must remain in service for vesting to occur. Such grants are common as compensation and do not directly signal buying or selling intent.
• Because no immediate exercise or sale occurred, this is not a cashless exercise or liquidity event; it's a compensation grant that may convert to owned shares over the vesting period.